ASPREE-D: Aspirin for the prevention of depression in the elderly.
Int Psychogeriatr
; 28(10): 1741-8, 2016 10.
Article
em En
| MEDLINE
| ID: mdl-27587328
ABSTRACT
BACKGROUND:
Not only is depression associated with increased inflammation but inflammation is a risk factor for the genesis of depression. Many of the environmental risk factors for depression are transduced through inflammatory signaling. Anti-inflammatory agents show promise for the management of depression in preclinical, epidemiological, and early clinical studies. This opens the door to the potential for anti-inflammatory agents to treat and prevent depression. There are no evidence-based pharmacotherapies for depression prevention.METHOD:
ASPREE-D, aspirin in the prevention of depression in the elderly, is a sub study of ASPREE, which explores the potential of aspirin to prevent a range of inflammation related disorders in the elderly. With a sample size of 19,114, and a duration of 5 years, this placebo controlled study will be one of the largest randomized controlled trials in psychiatry and will provide definitive evidence on the ability of aspirin to prevent depression.RESULTS:
This paper presents the rationale for the study and presents a summary of the study design.CONCLUSIONS:
ASPREE-D may not only define novel therapy but will provide mechanistic proof of concept of the role of inflammation in depression.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Aspirina
/
Depressão
/
Inflamação
Tipo de estudo:
Clinical_trials
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article